Cargando…

NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma

BACKGROUND: Macrophages and dendritic cells lacking the transcription factor nuclear factor kappa B p50 are skewed toward a proinflammatory phenotype, with increased cytokine expression and enhanced T cell activation; additionally, murine melanoma, fibrosarcoma, colon carcinoma, and glioblastoma gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suresh, Rahul, Barakat, David J, Barberi, Theresa, Zheng, Lei, Jaffee, Elizabeth, Pienta, Kenneth J, Friedman, Alan D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057444/ https://www.ncbi.nlm.nih.gov/pubmed/31940589 http://dx.doi.org/10.1136/jitc-2019-000244

Ejemplares similares

Adoptive transfer of immature myeloid cells lacking NF‐κB p50 (p50‐IMC) impedes the growth of MHC‐matched high‐risk neuroblastoma
por: Cui, Cheng, et al.
Publicado: (2021)

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies
por: Çınar, Özcan, et al.
Publicado: (2021)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma
por: Schaettler, Maximilian O, et al.
Publicado: (2023)

TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
por: Bi, Jiacheng, et al.
Publicado: (2023)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

B cells imprint adoptively transferred CD8(+) T cells with enhanced tumor immunity
por: Smith, Aubrey S, et al.
Publicado: (2022)

IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy
por: Kohli, Karan, et al.
Publicado: (2021)

'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies
por: Sinha, Debottam, et al.
Publicado: (2021)

Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy
por: Tourret, Marie, et al.
Publicado: (2021)

Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
por: Verdegaal, Els M E, et al.
Publicado: (2023)

Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
por: Braun, Mitchell W, et al.
Publicado: (2020)

Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo
por: Bunch, Brittany L, et al.
Publicado: (2020)

Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
por: Kverneland, Anders Handrup, et al.
Publicado: (2021)

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
por: Park, Jeong A, et al.
Publicado: (2021)

BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control
por: McGray, A J Robert, et al.
Publicado: (2023)

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
por: Tvingsholm, Siri Amanda, et al.
Publicado: (2023)

Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy
por: Aboelella, Nada S, et al.
Publicado: (2022)

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
por: Anderson, Kristin G, et al.
Publicado: (2022)

Neoantigen-specific CD4(+) tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients
por: Hall, MacLean S., et al.
Publicado: (2023)

Membrane anchored IL-18 linked to constitutively active TLR4 and CD40 improves human T cell antitumor capacities for adoptive cell therapy
por: Blokon-Kogan, Dayana, et al.
Publicado: (2022)

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study
por: Verdegaal, Els, et al.
Publicado: (2020)

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity
por: Legscha, Kevin Jan, et al.
Publicado: (2021)

Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
por: Kakimi, Kazuhiro, et al.
Publicado: (2020)

PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor–related cardiac dysfunction
por: Xia, Wenzheng, et al.
Publicado: (2020)

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022)

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
por: Chesney, Jason, et al.
Publicado: (2022)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Nanopore sequencing as a scalable, cost-effective platform for analyzing polyclonal vector integration sites following clinical T cell therapy
por: Zhang, Ping, et al.
Publicado: (2020)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
por: Zhang, Boning, et al.
Publicado: (2020)

CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation
por: Dragon, Anna Christina, et al.
Publicado: (2020)

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
por: Gardell, Jennifer L, et al.
Publicado: (2020)

Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells
por: Bajwa, Gagan, et al.
Publicado: (2020)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
por: Adams, Sarah F, et al.
Publicado: (2020)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
por: Velasco-Hernandez, Talia, et al.
Publicado: (2020)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
por: Iida, Yuichi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tq47c79ceumaq3enctkln7hq61